UOC
CMTA

UBS O'Connor’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

UBS O'Connor’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-39,339
Closed -$463K – 193
2018
Q4 		$463K Buy
+39,339
New +$489K 0.02% 199
2018
Q2 		– Sell
-43,866
Closed -$665K – 403
2018
Q1 		$665K Buy
+43,866
New +$714K 0.01% 252

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KLCMU
Kite Lake Capital Management (UK) London, United Kingdom $125M AUM 198.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

UBS O'Connor's CMTA Position: Q1 2019 in Review

UBS O'Connor sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q1 2019, closing a stake of 39,339 shares — an estimated $463K sold.

UBS O'Connor first reported a position in CMTA in Q1 2018 and held it in 2 quarters. The position peaked at $665K in Q1 2018. 48 funds tracked by Wall St. Rank hold CMTA as of Q1 2019.

  • UBS O'Connor reported no remaining Clementia Pharmaceuticals Inc. position as of Q1 2019 after selling out during the quarter.
  • UBS O'Connor sold 39,339 Clementia Pharmaceuticals Inc. shares in Q1 2019, an estimated $463K.
  • UBS O'Connor first reported a position in Clementia Pharmaceuticals Inc. in Q1 2018 and held it in 2 quarters.
  • UBS O'Connor's Clementia Pharmaceuticals Inc. position peaked at $665K in Q1 2018.
  • 48 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q1 2019.

Based on UBS O'Connor's 13F filing for Q1 2019, filed 13 May 2019.